Treatment of Peri-implant Mucositis and Supportive Peri-implant Therapy

Sponsor
University of Michigan (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06137846
Collaborator
(none)
60
1
2
9
6.7

Study Details

Study Description

Brief Summary

The investigators are evaluating the therapeutic outcomes of two cleaning instruments on treating peri-implant mucositis. Peri-implant mucositis is inflammation around an implant that is limited to only the gum tissue and is characterized by bleeding on probing, pus, and without any evidence of bone loss. The investigators wish to compare the amount of inflammation and bacteria through measurements (like probing depth) and by collecting fluid and plaque samples around participants' implant after using one of the two cleaning instruments.

Condition or Disease Intervention/Treatment Phase
  • Device: Air-Polish
  • Device: Ultrasonic
N/A

Detailed Description

Despite the potential benefits of an air-polishing device with erythritol powder, clinical trials using the device as a monotherapy for treating patients with peri-implant mucositis remained limited. Therefore, the primary aim of the present study is to compare clinical outcomes of the non-surgical treatment of peri-implant mucositis and subsequent supportive peri-implant therapy (SPIT) using an erythritol air-polishing device or conventional mechanical debridement. The secondary aim is to compare the resolution of inflammation after non-surgical treatment of peri-implant mucositis and to monitor levels of peri-implant tissues inflammation during supportive peri-implant therapy by using the level of selected pro-inflammatory cytokines.

Up to 60 participants with dental implants will be recruited from patients seeking and/or receiving dental care at the University of Michigan Graduate Periodontics department, until 34 peri-mucositis participants and 17 healthy participants are achieved.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Treatment of Peri-implant Mucositis and Supportive Peri-implant Therapy Using an Erythritol Air- Polishing Device Versus Conventional Mechanical Debridement: A 6-month Randomized Controlled Clinical Trial
Actual Study Start Date :
Oct 31, 2023
Anticipated Primary Completion Date :
Jul 31, 2024
Anticipated Study Completion Date :
Jul 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Peri-mucositis

Dental implant has peri-implant mucositis

Device: Air-Polish
Dental implant will be cleaned with an airpolishing device

Device: Ultrasonic
Dental implant will be cleaned with an ultrasonic device with a plastic tip

Placebo Comparator: Healthy

Dental implant does not have peri-implant mucositis

Device: Air-Polish
Dental implant will be cleaned with an airpolishing device

Outcome Measures

Primary Outcome Measures

  1. Probing depth measurements [Baseline, 2 weeks, 4 weeks, 3 months, and 6 months]

    To compare probing depth measurements in millimeters after non-surgical treatment of peri-implant mucositis

  2. Bleeding on probing scores (Mombelli et al.) [Baseline, 2 weeks, 4 weeks, 3 months, and 6 months]

    To compare bleeding on probing after non-surgical treatment of peri-implant mucositis. Possible scores range from 0 to 3, with higher scores indicating heavier bleeding.

  3. Plaque score (Loe & Silness) [Baseline, 2 weeks, 4 weeks, 3 months, and 6 months]

    To compare plaque scores after non-surgical treatment of peri-implant mucositis. Possible scores range from 0 to 3, with higher scores indicating greater plaque accumulation.

  4. Gingival index (Loe & Silness) [Baseline, 2 weeks, 4 weeks, 3 months, and 6 months]

    To compare gingival index scores after non-surgical treatment of peri-implant mucositis. Possible scores range from 0 to 3, with higher scores indicating greater inflammation.

  5. Gum recession measurement [Baseline, 2 weeks, 4 weeks, 3 months, and 6 months]

    To compare gum recession after non-surgical treatment of peri-implant mucositis

  6. Bone measurement [Baseline, 3 months, and 6 months]

    Loss of supporting bone measured by standardized radiographs

Secondary Outcome Measures

  1. Inflammatory cytokines levels [Baseline, 2 weeks, 4 weeks, 3 months, and 6 months]

    To compare changes in the level of inflammatory cytokines in peri-implant crevicular fluid (PICF)

  2. Bacterial DNA levels [Baseline, 2 weeks, 4 weeks, 3 months, and 6 months]

    To compare changes in the level of bacterial DNA of Aa, Pg, Pi, Tf, and Td in PICF

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  1. Age 18 to 85 years.

  2. Healthy systemic conditions (American Society of Anesthesiologists classification (ASA) I or II: systemically healthy or suffer from mild to moderate, but well controlled systemic diseases).

  3. Must have at least one osseointegrated dental implant with the following conditions (Berglundh et al. 2018a).

  • At least 12 months since the prosthesis was placed.

  • Absence of bone loss beyond crestal bone level changes from initial bone remodeling.

  • For implant mucositis subjects: Presence of bleeding and/or suppuration on gentle probing around implant at least 2 sites. Visual inspection demonstrating the presence of peri-implant signs of inflammation.

  • For healthy implant subjects: Absence of bleeding and/or suppuration on gentle probing around implant.

  1. Have a current (less than 6 months old) x-ray of the affected site

  2. All participants must be enrolled in a 3 to 6 months maintenance recall program including teeth/implants prophylaxis and supportive periodontal therapy.

Exclusion criteria:
  1. Poorly controlled diabetes mellitus (HbA1c >6.5).

  2. Uncontrolled systemic disease or condition known to alter bone metabolism. (e.g. osteoporosis, osteopenia, hyperparathyroidism, Paget's disease)

  3. Current smokers or vapers.

  4. Pregnancy or could be pregnant (self-reported), or plan to be pregnant in the next 6 months.

  5. Long-term (3 months) intake of anti-inflammatory medications (e.g. non-steroidal anti-inflammatory drugs (NSAIDs)) known to affect periodontal status within one month previous to participation in the study.

  6. Taking corticosteroids.

  7. Long-term antibiotic use (> one weeks) within three months previous to participation in the study.

  8. No history of supragingival scaling or non-surgical therapy at the affected implant site in the last 1 month.

  9. Taking anticoagulant medications.

  10. Subjects who require prophylactic antibiotics.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Michigan School of Dentistry Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • University of Michigan

Investigators

  • Principal Investigator: Hom-Lay Wang, DDS MSD PhD, Department of Periodontics and Oral Medicine University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hom-Lay Wang, DDS, MSD, Ph D, Collegiate Professor of Periodontics and Professor of Dentistry, University of Michigan
ClinicalTrials.gov Identifier:
NCT06137846
Other Study ID Numbers:
  • HUM00164918
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 21, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 21, 2023